What is ENDRA Life Sciences Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ENDRA Life Sciences's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ENDRA Life Sciences's Operating Income for the
three
months ended in Dec. 2023 was $ -1.46 Mil. ENDRA Life Sciences's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
GuruFocus does not calculate ENDRA Life Sciences's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ENDRA Life Sciences Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences (NAS:NDRA) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ENDRA Life Sciences's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-1.46 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $0.19 Mil.
ENDRA Life Sciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate ENDRA Life Sciences's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. ENDRA Life Sciences Inc has enough cash to cover all of its debt. Its financial situation is stable.
ENDRA Life Sciences (ENDRA Life Sciences) Business Description
Traded in Other Exchanges
N/A
Address
3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Executives
| Michael Milos Thornton |
officer: Chief Technology Officer |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Anthony Digiandomenico |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Alexander Y Tokman |
director |
C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052 |
| Francois Roger Michelon |
director, officer: Chief Executive Officer |
430 N. JUNO LANE, JUNO BEACH FL 33406 |
| Lou Basenese |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Irina Pestrikova |
officer: Senior Director, Finance |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Renaud Bertrand Maloberti |
officer: Chief Commercial Officer |
10 ACORN WAY, GEORGETOWN MA 01833 |
| David R. Wells |
officer: Chief Financial Officer |
2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405 |
| Michael Harsh |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Longboard Capital Advisors, Llc |
10 percent owner |
9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212 |
| Brett Conrad |
10 percent owner |
1312 CEDAR ST., SANTA MONICA CA 90405 |
| Sanjiv Sam Gambhir |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
ENDRA Life Sciences (ENDRA Life Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NDRA has been successfully added to your 